The Cystic Fibrosis care team has developed an integrated practice unit where multiple and multidisciplinary providers can evaluate patients during a single clinic visit and deliver state-of-the-art ...
Hector Gutierrez, M.D., professor at the UAB Marnix E. Heersink School of Medicine Department of Pediatrics, Division of Pulmonary and Sleep Medicine, founded Dream a Little Dream, UAB’s first ...
I spent my life planning for treatments and hospital stays — not retirement — because I never expected to grow old. Breakthrough therapies have changed that, leaving me grateful and now responsible ...
Supportive therapy, like medications to help open the airways and heal infections, can help you live a healthier life and meet many of the challenges of this inherited respiratory condition. Share on ...
The introduction of highly effective modulator (elexacaftor/tezacaftor/ivacaftor) therapy improved the disease trajectory of cystic fibrosis (CF). However, its ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
Atypical cystic fibrosis is a mild form of cystic fibrosis. People with this type of cystic fibrosis can experience symptoms that come and go or that are less severe than those people with classic ...
Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, ...
Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...
A 24-week phase 3 trial has found that once-daily vanzacaftor-tezacaftor-deutivacaftor is generally safe and well tolerated in children with cystic fibrosis aged 6-11 years. The treatment maintains ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results